The FDA-AER system database contained 162 cases of statin-induced ILD as of June 2007 (Table 2). The total number of reports associated with each drug was as follows: lovastatin, n = 14; simvastatin, n = 63; pravastatin, n = 23; atorvastatin, n = 47; fluvastatin, n = 5; rosuvastatin, n = 1; and cerivastatin, n = 9. The subjects were predominantly men (72%) with a mean age of 71 years. Since the 162 cases represent the absolute number of cases retrieved from the complete data set, it is difficult to predict the prevalence of statin-induced ILD in the general population. We calculated ILD report rates per 1,000,000 prescriptions for atorvastatin (0.07 per 1,000,000 prescriptions), simvastatin (0.18 per 1,000,000 prescriptions), and pravastatin (0.18 per 1,000,000 prescriptions). When the ratio of ILD reports to total adverse events reported were calculated for the various statins, we observed that for every 10,000 reports of a statin-associated adverse event, approximately 1 to 40 reports were for an ILD, with the lowest ratio observed with rosuvastatin (1 in 10,000) and the highest with simvastatin (4 in 1,000) [Table 2].